Dementia, Mortality Risk Up for GBA Carriers With Parkinson's

This article originally appeared here.
Share this content:
Dementia, Mortality Risk Up for <i>GBA</i> Carriers With Parkinson's
Dementia, Mortality Risk Up for GBA Carriers With Parkinson's

THURSDAY, Sept. 22, 2016 (HealthDay News) -- Parkinson's disease (PD) patients with glucocerebrosidase gene (GBA) mutations have increased risk for dementia and death, according to a study published online Sept. 15 in the Annals of Neurology.

Roberto Cilia, M.D., from the Parkinson Institute in Milan, and colleagues examined survival, dementia, and genotype-phenotype correlations in 2,764 unrelated PD patients, including 123 GBA carriers and 2,641 non-carriers. They analyzed brain perfusion and dopamine transporter imaging, including dementia with Lewy bodies (DLB) as an additional control group.

The researchers found that GBA carriers were at greater risk for dementia and death (hazard ratios, 3.16 and 1.85, respectively) than non-carriers in multivariable analysis adjusted by gender, age at onset, and disease duration. The mortality risk remained greater in carriers when dementia was introduced as a time-dependent covariate in the model (hazard ratio, 1.65). GBA carriers had worse motor symptoms, especially non-dopaminergic features, at last examination. The risk for dementia was increased for carriers of severe versus mild mutations; mortality risk was similar. Compared with PD non-carriers, GBA carriers exhibited reduced posterior parietal and occipital cortical synaptic activity and nigrostriatal function. Mild mutation carriers had neuroimaging features that overlapped with PD non-carriers, while carriers of severe mutations were more similar to DLB.

"Survival is reduced in GBA carriers compared to non-carriers; this seems to be partially independent from the increased risk for early dementia," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »